汉森制药(002412) - 2025年9月19日投资者关系活动记录表

Group 1: Company Strategy - The company's main business is traditional Chinese medicine, and it has invested in Sanxiang Bank, which has led to financial losses. The company emphasizes that the investment is part of its "one body, two wings" development strategy, integrating traditional medicine with the health and financial industries [2]. - The company will disclose any significant matters related to the transfer of Sanxiang Bank's equity in a timely manner [2]. Group 2: Future Plans - There is a question regarding whether the company has plans to acquire Kangpu Pharmaceutical after the major shareholder Liu Ling'an increased his stake in 2021. The company stated that any future acquisition matters will also be disclosed promptly [2].